Our purpose was to incorporate regulation into the recombinant adeno-associated virus encoding leptin by introducing a tet-inducible promotor. This system, TET-Ob, allows for control of leptin gene expression via doxycycline in drinking water. F344XBN rats (aged 4 months) were given a hypothalamic injection of TET-Ob or control virus. During 34 days of doxycycline (doxy) administration to all rats (STAGE 1), TET-Ob rats gained 50.7% less mass, ate 10.4% less food, and had a 77.5% reduction in serum leptin as compared with controls. Doxy was then withdrawn from half of the TET-Ob rats for 32 days (TET-Ob-OFF), while half continued to receive doxy (TET-Ob-ON) (stage 2). During stage 2, TET-
Introduction
Leptin, the product of the Ob gene, acts on satiety centers in the hypothalamus to both decrease food intake and increase energy expenditure. Virus-mediated leptin gene delivery has been shown to cause a rapid and complete disappearance of white adipose tissue in genetically normal animals. 1 Leptin gene delivery is substantially more effective in correcting genetic obesity than daily leptin infusion, despite higher peak serum leptin levels with the latter. 2 Peripheral administration of virally encoded leptin requires that the leptin crosses the blood-brain barrier (BBB) to reach its primary hypothalamic targets, but this transport system is saturated at serum leptin levels seen in obese animals. 3 Since several obese, leptin-resistant models respond better to central versus peripheral administration of recombinant leptin, [4] [5] [6] it has been reasoned that central delivery of the leptin gene would be superior to peripheral delivery. 7 Indeed, central delivery of virally encoded leptin causes dramatic lipopenia, while avoiding systemic hyperleptinemia and the limitations of BBB transport. 7, 8 The main limitation of viral-mediated leptin-gene therapy systems studied to date is the lack of post-transfec-
Ob-ON rats gained 44.8% less mass than TET-Ob-OFF and ate significantly less food than both TET-Ob-OFF and controls. Serum leptin increased to 83.4% of control values in TET-Ob-OFF, but remained very low in the in TET-Ob-ON. At death, visceral adiposity was 14.5% of controls in TETOb-ON animals, but had risen to 76.9% of controls in TETOb-OFF. A reversible increase in both leptin signal transduction in the hypothalamus and uncoupling protein expression in brown adipose was recorded. This system allows for more precise regulation of gene therapy-mediated fat loss.
Gene Therapy (2002) 9, 1492-1499. doi:10.1038/sj.gt.3301835 tional control. This is undesirable clinically as it would be difficult or impossible to reverse the progression of deleterious side-effects as they appeared. Given leptin's diverse biological functions, central overexpression of leptin (coupled with a precipitous fall in serum leptin) could compromise the immune 9 and reproductive systems. 10 Central leptin signaling is also known to decrease bone mass. 11 Peripheral overexpession of leptin, on the other hand, leads to pancreatic beta cell disfunction 12 and up-regulates suppressor of cytokine signaling, which may interfere with insulin signaling. 13 We have attempted to solve these problems of uninhibited transgene expression by placing leptin under the control of the tetracycline transactivator (rtTA) and operon (tetR). In this dual-vector system, one vector encodes the tetR promotor and the leptin gene, while an assessory vector encodes rtTA and a transcriptional silencer (tTS) (Figure 1 ). This dual vector 'TET-Ob' system allows for the control leptin transgene expression via doxycycline (doxy) in drinking water. To this end, we administered the TET-Ob dual-vector system into the hypothalami of young adult, non-obese rodents, and examined the effects on anorectic signaling in the brain, peripheral thermogenesis and adiposity. Moreover, we determined if these effects can be completely reversed if the transgene is silenced. 
Results

Food consumption and body mass
Beginning on day 9 after transfection, doxy was provided in the drinking water of all animals for 34 days (stage 1), presumably activating the leptin transgene in all TET-Obtreated animals. During stage 1, TET-Ob rats gained 51.7 % less mass ( Figure 2 , between arrows) and ate 11.4% less food (Figure 3 ) than controls. To begin stage 2, the TET-Ob group was divided into two subgroups. Doxy was withdrawn from half of the TET-Ob-treated animals for 32 days (TET-Ob-OFF) while half continued to receive doxy (TET-Ob-ON). During stage 2, TET-Ob-ON rats gained 44.8% less mass than TET-Ob-OFF rats (Figure 2) , and ate significantly less food than both TET-Ob-OFF and controls ( Figure 3) . Rates of body mass gain were not different between TET-Ob-ON and controls during stage 2. The same degree of anorexia was maintained in TET-Ob-ON animals throughout both stages of the study. Doxy/saccharin did not affect fluid intake (data not shown).
Serum leptin and adiposity
Consistent with leptin-dependent catabolism of adipose tissue in TET-Ob rats, serum leptin fell to 22.5% of control values during stage 1 (Figure 4 ). During stage 2, serum leptin increased to 83.4% of control values in the TETOb-OFF animals, but remained very low (21.9% of controls) in the TET-Ob-ON group (Figure 4 ). At death, average visceral adiposity (sum of retroperitoneal white adipose (RTWAT) and perirenal white adipose (PWAT) depots) was 14.6% of controls in TET-Ob-ON animals ( Figure 5 ), and three of the seven TET-Ob-ON had no visible intra-abdominal adipose tissue. Visceral adiposity was 76.9% of controls in TET-Ob-OFF at death, suggest- ing these animals recovered adipose tissue during stage 2 ( Figure 5 ).
Serum free fatty acids, insulin and glucose
At death, average serum free fatty acids were 15.2% lower in the TET-Ob-ON group compared with the TETOb-OFF group and were 12.5% lower in TET-Ob-ON versus controls. Neither of these findings was statistically significant after employing the Bonferroni correction for multiple comparisons. Serum insulin was significantly reduced in the TET-Ob-ON as compared with both controls and TET-Ob-OFF (Table 1) . Serum glucose was unaffected by treatment (Table 1) .
Leptin expression
Leptin expression in the hypothalamus of TET-Ob-ON animals was increased 8.5-fold versus controls ( Figure 6 ). The level of hypothalamic leptin expression did not differ significantly between TET-Ob-OFF and control, suggesting that the transgene was silenced when doxy was withdrawn.
Signal transduction in hypothalamus
Hypothalamic phosphorylated STAT3 (P-STAT3), a component of the leptin-signaling cascade, was elevated by 46% in TET-Ob-ON group, but not TET-Ob-OFF ( Figure 7 ). Total STAT3 was not affected (data not shown). It is believed that an increase in POMC expression (the precursor to ␣-MSH) contributes to the anorectic effect of leptin.
14 In this study, hypothalamic POMC mRNA was found to be elevated by 41.2% in TETOb-ON animals versus controls and by 16.4% versus TETOb-OFF ( Figure 8 ). Leptin is also known to up-regulate expression of suppressor of cytokine signaling (SOCS3). 8, 15 SOCS3 mRNA was increased by 67.3% in TET-Ob-ON versus controls and by 34.9% versus TET-Ob-OFF ( Figure 9 ). Finally, leptin signaling is known to depress NPY expression in arcuate neurons. 13 However, we did not detect any differences in NPY expression (100.0 ± 12.4 arbitrary units in control, 94.9 ± 19.7 in TETOb-ON, 115.8 ± 10.0 in TET-Ob-OFF).
Brown adipose tissue
TET-Ob-ON animals had a three-fold increase in UCP-1 protein levels per unit of BAT compared with both controls and TET-Ob-OFF (Table 1) . Furthermore, TET-Ob-ON animals tended to have elevated UCP-1 mRNA in BAT compared with TET-Ob-OFF and controls (Table 1) . Consistent with activated BAT in the TET-Ob-ON group, their BAT appeared dark red, whereas the BAT extracted from both controls and TET-Ob-OFF animals appeared pale brown (dormant). Total BAT tissue mass declined in the TET-Ob-ON animals, while the protein concentration (per unit BAT) increased ( Table 1 ), suggesting that the decrease in mass was due to lipolysis. Even when the decrease in BAT mass is accounted for, there was still a two-fold increase in UCP-1 protein per total interscapular BAT pad in TET-Ob-ON compared with both controls and TET-Ob-OFF (Table 1 ).
Discussion
We hypothesized that a direct hypothalamic injection of rAAV encoding leptin under control of the tetracycline transactivator and operon (TET-Ob) would allow us to regulate leptin transgene expression and the subsequent anorexic and thermogenic effects. In animals given the TET-Ob system, we demonstrated a reversible suppression in the rate of body mass gain and reversible anorexia. There was a dramatic 85.4% reduction in adiposity in TET-Ob animals continuously administered doxycycline for 66 days (TET-Ob-ON). In a subpopulation of TET-Ob animals from which we withdrew Doxy (TET-Ob-OFF), visceral adiposity was indistinguishable from controls. We believe this represents a recovery of adiposity in TET-Ob-OFF animals during stage 2. Consistent with the adiposity data, serum leptin was 22.5% of control levels in TET-Ob at the end of stage 1. By the end of stage 2, serum leptin in the TET-Ob-OFF was similar to controls and nearly quadruple the serum leptin in the TET-Ob-ON. Hypothalamic leptin expression was increased 8.5-fold in the TET-Ob-ON animals, and this was reversed in TET-Ob-OFF. Leptin signal transduction and changes in the expression of POMC and SOCS3 in the hypothalamus were also consistent with a reversible increase in central leptin activity. UCP-1 protein levels per unit BAT tripled in TET-Ob-ON animals and this increase was completely reversed in TET-Ob-OFF. Finally, serum insulin was reduced in the TET-Ob-ON but not TET-Ob-OFF group.
In the first leptin gene therapy study, Chen et al demonstrated that an i.v. infusion of adenovirus (Ad) encoding leptin maintained hyperleptinemia for 28 days and resulted in a complete disappearance of white adipose tissue in Wistar rats.
1 Pair-fed animals experienced a modest reduction in adiposity despite similar weight loss, thus revealing that leptin gene therapy triggers an unprecedented, selective catabolism of white fat. 1 Given that uptake of leptin across the BBB appears to be a satuGene Therapy rable process, it has recently been hypothesized that central delivery of the leptin gene may be more therapeutically efficacious in models resistant to peripheral leptin. 7 In a recent investigation, central delivery of the leptin gene using an Ad vector resulted in both anorexia and weight loss in the normally leptin-resistant obese fa/fa rat. 16 However, leptin transgene expression appeared to decrease dramatically between day 7 and 14 after transfection, as did physiological responses. This transient transgene expression could be the biproduct of a hostimmune response that appears to be mounted in response to adenoviral antigens. 17 Recombinant adeno-associated virus appears to circumvent the limitations of Ad. 18 The rAAV vector lacks virally encoded genes, thus eliminating the risk of immune response to viral-specific antigens. Moreover, rAAV-mediated gene delivery results in unabated transgene expression for at least 6 months, 19 whereas transgene expression appears to decline within days after Ad vector delivery. 16, 20 Further, rAAV gene delivery is suitable for delivery directly into neuronal tissue. 21 This allows for transgene expression in the CNS, thus bypassing potential limitations of blood-brain barrier transport. For all of these reasons, rAAV appears to be the superior vector for leptin gene delivery.
In the present study, the leptin gene was delivered centrally by rAAV, thereby avoiding both the problem of saturable BBB transport and the problem of unpredictable silencing of transgene with Ad. Moreover, this is the first study to incorporate regulation into leptin gene therapy -presumably a desirable feature for any gene delivery system to be studied in humans. The importance of post-transfectional control becomes clear when one considers the potential side-effects of leptin transgene overexpression. For example, a single intracerebroventricular (i.c.v) injection of constitutively active rAAV-leptin was recently shown to impair T-lymphocyte-mediated immunity in rats. 22 As discussed previously, leptin overexpression could also have negative effects on the reproductive system 10 and skeletal system. 11 Should such sideeffects appear, transgene expression could be reduced or silenced if the gene delivery system incorporates regulation. This is the principle advantage of the TET-Ob system described here. Without such regulation, one would have to resort to complicated (and likely less effective) pharmacological strategies or antisense delivery to reduce the severity of side-effects.
The results of this study support the finding of our earlier investigation 8 in that there is no apparent leptindependent desensitization of leptin signal transduction in the absence of obesity. In our previous report using constitutively active leptin gene delivery, hypothalamic P-STAT3, a primary Ob-RB (long form leptin receptor) second messenger, was elevated to the same extent 9 and 46 days after transfection. In the present study, hypothalamic P-STAT3 remained elevated 66 days after beginning doxy administration in the TET-Ob-ON group. This was despite an increase in expression of SOCS3, a putative negative regulator of leptin signaling, in the hypothalamus. No elevation in hypothalamic P-STAT3 was detected in the TET-Ob-OFF group, confirming that the amplified leptin signal transduction in the Ob-ON group was dependent on the externally regulated leptin transgene expression. Moreover, POMC mRNA levels in the hypothalamus and UCP-1 in BAT mirrored hypothalamic P-STAT3 levels, implying that there was no desensitization anywhere downstream of the leptin receptor. The physiological data confirm that the TET-Ob-ON animals remained responsive to the transgene as anorexia continued through the final days of the study. These results suggest that leptin overexpression in itself does not lead to leptin resistance in a non-obese model, or at least not over the duration of the present study. Thus, the leptin resistance previously reported in both obese humans 23 and animals 24, 25 may not be a simple biproduct of chronic hyperleptinemia, but rather a feature specific to obesity itself. It is also possible that a combination of both chronic hyperleptinemia and obesity are required for leptin resistance, as suggested by our most recent investigation. 26 Further research is needed to discern what factor(s) link obesity and leptin resistance.
One surprising finding was that NPY expression was not significantly depressed in the TET-Ob-ON group at death. This is particularly perplexing in light of the increased POMC expression in TET-Ob-ON, as leptin signaling has been shown to have opposite and simultaneous effects on POMC and NPY expressing neurons. 14, 27 In previous studies, we have reliably detected reduced hypothalamic NPY mRNA following central leptin peptide and leptin gene delivery. 8, 24 One possibility is that the TET-Ob-mediated enhanced leptin signaling did, indeed, suppress NPY expression, but to an extent that was too small for us to detect. A second possibility is that at some time before day 66, compensatory pathways reversed the effects of the transgene on NPY expression. Our previous constitutively active leptin gene therapy trial was 20 days shorter, which may not have been long enough for this compensatory pathway to override leptin's effect on NPY expression. 8 The sum of these results demonstrates that the TETOb system allows for post-transfection control of leptin transgene expression, and ergo leptin signaling and associated biochemical and physiological responses. Although this experiment examined only an 'on' and 'off' state, it is known that expression of genes under the control of the TET operon occurs in a doxy-dose dependent manner. 28 This suggests that by adjusting the dose of doxy, this system could be used to titer leptin expression to achieve optimal levels of adiposity while minimizing side-effects. Construction of rAAV vector plasmid pTR-tetR-Ob (Figure 1a ) encodes rat leptin cDNA (a kind gift from Roger Unger 1 and green fluorescent protein (GFP) reporter gene cDNA under the control of a tetinducible promotor (tetR). The woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was placed downstream to enhance the expression of the transgenes. 29 The control vector encodes GFP driven by a CBA. This tetR promoter is activated by the product of the accessory vector, pTR-rtTA/tTS (Figure 1b) , expressing mutually exclusive reverse transactivator rtTA (TetOn) and transcriptional silencer (tTS). In the accessory vector, the rtTA and tTS transgenes are linked within dicistronic cassettes through an IRES element for coordinate expression. All vectors contain AAV terminal repeats at both sides of the cassette to mediate replication and packaging of the vector.
Materials and methods
Animals
30
Packaging of rAAV vectors Vectors were packaged, purified, concentrated and titered as described previously. 18 The titers of rAAV-tetROb and rAAV-AS (accessory virus) used were 6.6E12 and 1.37E12 infectious particles/ml, respectively. A miniadenovirus helper plasmid (pDG) 31 was used to produce rAAV vectors with no detectable adenovirus or wild-type AAV contamination. rAAV vectors were purified using iodixanol gradient/heparin-affinity chromatography and were more than 99% pure as judged by PAAG/silverstained gel electrophoresis (not shown).
Vector administration
Rats were anesthetized with 60 mg/kg pentobarbital and heads were prepared for surgery. Animals were placed into a stereotactic frame and a small incision (1.5 cm) was made over the midline of the skull to expose the landmarks of the cranium (bregma and lamda). The following coordinates were used for injection into the right anterior hypothalamus: 1.8 mm posterior to bregma, 0.8 mm right of midline (medial fissure), and 9.0 mm ventral from the skull surface. The nose bar was set at zero (on same plane with ear bars) and the canula was set vertically. A small hole was drilled through the skull and a 23-gauge stainless steel guide canula was lowered to the hypothalamus. This was followed by an injection canula attached to a 10 l syringe. We injected 5 l of viral particles in Ringer's solution at approximately 0.25 l min. Animals received either the two-vector TET-Ob system (n = 14) or control virus encoding GFP (n = 6).
Experimental design
This experiment is divided into two stages. During stage 1, doxycycline hydrochloride (Sigma, St Louis, MO, USA) (400 g/ml) and 0.1% saccharine (Sigma) were provided in the drinking water of all animals beginning day 9 after transfection. All rats received doxy for a total of 34 days, and this period is designated as stage 1. At the end of stage 1, doxy was withdrawn from half of the TET-Ob rats for 32 days (TET-Ob-OFF) while half continued to Gene Therapy receive Doxy (TET-Ob-ON). This second phase of the study is designated as stage 2. Controls received doxy throughout the study (ie both stage 1 and stage 2).
Tissue harvesting
Rats were anesthetized with 85 mg/kg pentobarbital and killed by cervical dislocation. Blood was collected by cardiac puncture and serum was harvested by a 10-min centrifugation in serum separator tubes. The circulatory system was perfused with 20 ml of cold saline. Inguinal, perirenal and retroperitoneal white adipose tissue, brown adipose tissue, and hypothalami were excised, weighed and immediately frozen in liquid nitrogen. The hypothalamus was removed by making an incision medial to the piriform lobes, caudal to the optic chiasm, and anterior to the cerebral crus to a depth of 2-3 mm. Tissues were stored at -80°C until analysis.
Serum leptin, FFA, insulin and glucose
Serum leptin and insulin were measured using rat radioimmunoassay kits (Linco Research, St Charles, MO, USA). Serum-free fatty acids were measured using the NEFA C colorimetric kit from WAKO Chemicals (Neuss Germany). Serum glucose was via a colorimetric reaction with Trinder, the Sigma Diagnostics Glucose reagent (Sigma).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Leptin transgene expression was identified by using relative quantitative RT-PCR through the use of QuantumRNA 18s Internal Standards kit (Ambion, Austin, TX, USA). Total RNA (3 g) was treated with RNase-free DNase using a DNA-free kit (Ambion), and first-strand cDNA synthesis was generated from 1 g RNA in a 20 l volume using random primers (Gibco BRL) containing 200 units of M-MLV reverse transcriptase (Gibco BRL). Relative PCR was performed by multiplexing leptin primers (sense: 5'GGAGGAATCC-CTGCTCCAGC; antisense: 5' CCTCTCCTGAGGATACCTGG) and 18S primers. Linearity for the leptin amplicon was determined to be 25-30 cycles. The optimum ratio of 18S primer to competimer was 1:9. PCR was performed at 94°C denaturation for 120 s, 59°C annealing temperature for 60 s, and 72°C elongation temperature for 120 s for 27 cycles. The PCR product was electrophoresed on a 5% acrylamide gel and stained with SYBR green (Molecular Probes, Eugene, OR, USA). Gels were scanned using a STORM fluorescent scanner and digitized data analyzed using Imagequant (Molecular Dynamics).
STAT3/Phospo-STAT3 assay
These methods have been described in detail previously. 32 Briefly, hypothalamus was sonicated in 10 mM Tris-HCL, pH 6.8, 2% SDS, and 0.08 g/ml okadaic acid plus protease inhibitors (PMFS, benzamidine, and leupeptin) (an aliquot of this sonicate was frozen for RNA analysis). Sonicate was diluted and quantified for protein using a detergent compatible Bradford assay. Samples were boiled and separated on an SDS-PAGE gel and electrotransferred to nitrocellulose membrane. Immunoreactivity was assessed with an antibody specific to phosphorylated-STAT3 (antibody kit from New England Biolabs, Beverly, MA, USA). Immunoreactivity was visualized by chemiluminescence detection (Amersham Life Sciences) and quantified by video densitometry (BioRad, Hercules, CA, USA). Following P-STAT3 quantification, membranes were stripped of antibody (Pierce, Rockford, IL, USA) and immunoreactivity was re-assessed using a total STAT-3 antibody.
mRNA levels
Tissue was sonicated in guanidine buffer, phenol extracted and isopropanol precipitated using a modification of the method of Chomczynski and Sacchi. 33 Isolated RNA was quantified by spectrophotometry and integrity was verified using 1% agarose gels stained with ethidium bromide. For dot blot analysis, multiple concentrations of RNA were immobilized on nylon membranes using a dot blot apparatus (BioRad, Richmond, CA, USA). Membranes were baked in a UV crosslinking apparatus. Membranes were then prehybridized in 10 ml Quickhyb (Stratagene, La Jolla, CA, USA) for 30 min followed by hybridization in the presence of a labeled probe and 100 g salmon sperm DNA. After hybridization for 2 h at 65°C, the membranes were washed and exposed to a phosphor imaging screen for 24-72 h (depending on the anticipated strength of the signal). The screen was then scanned using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA, USA) and analyzed by Image Quant Software (Molecular Dynamics).
Statistical analysis
Comparisons between control and TET-Ob were made using unpaired t tests with a one-tailed P value. For stage 2 and endpoint statistics, relevant pairwise comparisons were made using unpaired t tests with the Bonferroni correction for multiple comparisons applied to ␣ level, which was set at 0.05. GraphPad Prism software (San Diego, CA, USA) was used for all statistical analysis and graphing.
